Hirudin biosimilar - Kerun Biopharmaceutical

Drug Profile

Hirudin biosimilar - Kerun Biopharmaceutical

Alternative Names: recombinant hirudin - Kerun Biopharmaceutical

Latest Information Update: 15 Apr 2016

Price : $50

At a glance

  • Originator Kerun Biopharmaceutical
  • Class Antithrombins; Hirudins
  • Mechanism of Action Thrombin inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase I Thrombosis

Most Recent Events

No Data Available
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top